Los Angeles, CA: The adjunctive administration of the proprietary, plant-derived CBD extract Epidiolex is associated with the complete remission of seizures in a 12-year old patient with super-refractory status epilepticus (SRSE), according to a case report published in the journal Epilepsy & Behavior Case Reports.
Investigators at the David Geffen School of Medicine in Los Angeles reported on the "prompt and enduring response that accompanied the adjunctive administration of CBD" in a patient with SRSE. Epilepticus status is defined as having either multiple seizures within a five-minute period or experiencing seizures lasting longer than five minutes. SRSE is defined as epilepticus that continues or recurs at least 24 hours after the onset of anesthesia.
Authors reported that the patient experienced the "complete resolution of SRSE upon exposure to pure cannabidiol."
In June, the US Food and Drug Administration approved Epidiolex for the US market to be available by prescription for the treatment of pediatric epilepsy.
For more information, contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, "Successful use of pure cannabidiol for the treatment of super-refractory status of epilepticus," appears in Epilepsy & Behavior Case Reports.